FDA Panel Endorses Arena's New Obesity Drug
A panel of U.S. Food and Drug Administration scientists gave its endorsement to Arena Pharmaceuticals Inc.'s obesity drug lorcaserin on Thursday, finding that the potential benefits of the medication outweigh the...To view the full article, register now.
Already a subscriber? Click here to view full article